411 related articles for article (PubMed ID: 19443146)
1. Characterization of a new inhalable thymopentin formulation.
Wang L; Zhang Y; Tang X
Int J Pharm; 2009 Jun; 375(1-2):1-7. PubMed ID: 19443146
[TBL] [Abstract][Full Text] [Related]
2. Dry powder inhalations containing thymopentin and its immunomodulating effects in Wistar rats.
Gao J; Ding X; Chu C; Lu L; Zhang Y; Chen Y; Fan W; Li G; Gao S
Eur J Pharm Sci; 2009 Mar; 36(4-5):572-9. PubMed ID: 19135531
[TBL] [Abstract][Full Text] [Related]
3. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
You Y; Zhao M; Liu G; Tang X
J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
[TBL] [Abstract][Full Text] [Related]
4. The influence of formulation components on the aerosolisation properties of spray-dried powders.
Rabbani NR; Seville PC
J Control Release; 2005 Dec; 110(1):130-40. PubMed ID: 16226334
[TBL] [Abstract][Full Text] [Related]
5. Development of inhalable dry powder formulation of basic fibroblast growth factor.
Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
Minne A; Boireau H; Horta MJ; Vanbever R
Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
[TBL] [Abstract][Full Text] [Related]
7. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
Cheow WS; Ng ML; Kho K; Hadinoto K
Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
[TBL] [Abstract][Full Text] [Related]
8. Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance.
Yang Y; Yang Z; Ren Y; Mei X
Drug Deliv; 2014 Sep; 21(6):480-6. PubMed ID: 24491208
[TBL] [Abstract][Full Text] [Related]
9. Aerosolization properties, surface composition and physical state of spray-dried protein powders.
Bosquillon C; Rouxhet PG; Ahimou F; Simon D; Culot C; Préat V; Vanbever R
J Control Release; 2004 Oct; 99(3):357-67. PubMed ID: 15451594
[TBL] [Abstract][Full Text] [Related]
10. Influence of potential inhalation carriers on stability of thymopentin in rat bronchoalveolar lavage fluid.
Cai C; Wang L; Dong W; Tang X
Drug Deliv; 2014 Sep; 21(6):495-500. PubMed ID: 24611940
[TBL] [Abstract][Full Text] [Related]
11. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.
Bosquillon C; Lombry C; Préat V; Vanbever R
J Control Release; 2001 Feb; 70(3):329-39. PubMed ID: 11182203
[TBL] [Abstract][Full Text] [Related]
12. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A
Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301
[TBL] [Abstract][Full Text] [Related]
13. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
14. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
15. Optimization and characterization of dry powder of fanhuncaoin for inhalation based on selection of excipients.
Yang XB; Wang XB; Pan WS; Xi RG; Wang YN; Liu D; Shi Y; Jiang S
Chem Pharm Bull (Tokyo); 2011; 59(8):929-37. PubMed ID: 21804235
[TBL] [Abstract][Full Text] [Related]
16. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations.
Devrim B; Bozkır A; Canefe K
Drug Dev Ind Pharm; 2011 Nov; 37(11):1376-86. PubMed ID: 21548727
[TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
Razavi Rohani SS; Abnous K; Tafaghodi M
Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
[TBL] [Abstract][Full Text] [Related]
18. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin.
Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
Int J Pharm; 2010 Apr; 389(1-2):74-85. PubMed ID: 20085803
[TBL] [Abstract][Full Text] [Related]
19. Effervescent dry powder for respiratory drug delivery.
Ely L; Roa W; Finlay WH; Löbenberg R
Eur J Pharm Biopharm; 2007 Mar; 65(3):346-53. PubMed ID: 17156987
[TBL] [Abstract][Full Text] [Related]
20. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.
Shetty N; Park H; Zemlyanov D; Mangal S; Bhujbal S; Zhou QT
Int J Pharm; 2018 Jun; 544(1):222-234. PubMed ID: 29678544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
